PTC Therapeutics retains Efficiency (Sharpe Ratio) of 0.1686 which implies the corporation had 0.1686% of return per unit of risk over the last 1 month. Our philosophy in forecasting volatility of a stock is to use all available market data together with stock specific technical indicators that cannot be diversified away. We have found twenty-one technical indicators for PTC Therapeutics which you can use to evaluate future volatility of the company. Please employ PTC Therapeutics Semi Deviation of 1.74 and Market Risk Adjusted Performance of 5.54 to confirm if our risk estimates are consistent with your expectations. " name="Description" /> PTC Therapeutics retains Efficiency (Sharpe Ratio) of 0.1686 which implies the corporation had 0.1686% of return per unit of risk over the last 1 month. Our philosophy in forecasting volatility of a stock is to use all available market data together with stock specific technical indicators that cannot be diversified away. We have found twenty-one technical indicators for PTC Therapeutics which you can use to evaluate future volatility of the company. Please employ PTC Therapeutics Semi Deviation of 1.74 and Market Risk Adjusted Performance of 5.54 to confirm if our risk estimates are consistent with your expectations. " /> PTC Therapeutics retains Efficiency (Sharpe Ratio) of 0.1686 which implies the corporation had 0.1686% of return per unit of risk over the last 1 month. Our philosophy in forecasting volatility of a stock is to use all available market data together with stock specific technical indicators that cannot be diversified away. We have found twenty-one technical indicators for PTC Therapeutics which you can use to evaluate future volatility of the company. Please employ PTC Therapeutics Semi Deviation of 1.74 and Market Risk Adjusted Performance of 5.54 to confirm if our risk estimates are consistent with your expectations. " />

PTC Therapeutics to continue advance in January

All Stories . Valuation . 
Rifka Kats .  Story
Rifka Kats
By Rifka Kats
Macroaxis Story
Is PTC Therapeutics valuation justified? Here I will cover the organisation prospective on valuation to give you a better outlook on taking a position in this stock. Macroaxis considers PTC Therapeutics not too volatile given 1 month investment horizon. PTC Therapeutics retains Efficiency (Sharpe Ratio) of 0.1686 which implies the corporation had 0.1686% of return per unit of risk over the last 1 month. Our philosophy in forecasting volatility of a stock is to use all available market data together with stock specific technical indicators that cannot be diversified away. We have found twenty-one technical indicators for PTC Therapeutics which you can use to evaluate future volatility of the company. Please employ PTC Therapeutics Semi Deviation of 1.74 and Market Risk Adjusted Performance of 5.54 to confirm if our risk estimates are consistent with your expectations.
Published over a year ago
View all stories for PTC Therapeutics | View All Stories
Macroaxis uses a strict editorial review process to publish stories and blog posts. Our publishers support our company and may receive a small commission when the partner links or references are utilized. Commissions do not affect the opinions or evaluations of our editorial team. The information our editors and media partners deliver is confidential and licensed for your sole use as a Macroaxis user. We reserve all rights to the content of this article, and therefore copying or distributing this story in whole or in part is strictly prohibited.

Reviewed by Raphi Shpitalnik

This firm currently holds 327.21 M in liabilities with Debt to Equity (D/E) ratio of 49.3 indicating the company may have difficulties to generate enough cash to satisfy its financial obligations. PTC Therapeutics dividends can provide a clue to current valuation of the stock. The firm is not expected to issue dividends this year as it trying to preserve or re-invest any of the funds available for distribution to stakeholders. Lets now take a look at PTC Therapeutics Market Capitalization. Based on recorded statements the market capitalization of PTC Therapeutics is about 3.02 B. This is 76.66% lower than that of the Healthcare sector, and 36.3% lower than that of Biotechnology industry, The Market Capitalization for all stocks is 84.13% higher than the firm.
We determine the current worth of PTC Therapeutics using both absolute as well as relative valuation methodologies to arrive at its intrinsic value. In general, an absolute valuation paradigm, as applied to this company, attempts to find the value of PTC Therapeutics based exclusively on its fundamental and basic technical indicators. By analyzing PTC Therapeutics's financials, quarterly and monthly indicators, and related drivers such as dividends, operating cash flow, and various types of growth rates, we attempt to find the most accurate representation of PTC Therapeutics's intrinsic value. In some cases, mostly for established, large-cap companies, we also incorporate more traditional valuation methods such as dividend discount, discounted cash flow, or asset-based models. As compared to an absolute model, our relative valuation model uses a comparative analysis of PTC Therapeutics. We calculate exposure to PTC Therapeutics's market risk, different technical and fundamental indicators, relevant financial multiples and ratios, and then comparing them to PTC Therapeutics's related companies.

PTC Therapeutics Investment Alerts

PTC investment alerts and warnings help investors to get more proficient at understanding not only critical technical and fundamental signals but also the significant portfolio-centered indicators. These indicators include beta, alpha, and other risk-related measures that will help you in monitoring PTC Therapeutics performance across your portfolios.Please check all investment alerts for PTC

PTC Therapeutics Valuation Ratios as Compared to Competition

Our valuation model uses many indicators to compare PTC value to that of its competitors to determine the firm's financial worth. You can analyze the relationship between different fundamental ratios across PTC Therapeutics competition to find correlations between indicators driving the intrinsic value of PTC.

PTC Therapeutics Gross Profit

PTC Therapeutics Gross Profit growth is one of the most critical measures in evaluating the company. The Gross Profit growth rate is calculated simply by comparing PTC Therapeutics previous period's values with its current period's values. Each time period you're measuring should be of equal lengths the increase or decrease, in a company's Gross Profit between two periods. Here we show PTC Therapeutics Gross Profit growth over the last 10 years. Please check PTC Therapeutics' gross profit and other fundamental indicators for more details.

Is PTC Therapeutics valued wisely by the market?

PTC Therapeutics owns negative utilization of current and long term assets of -7.4 %, securing only $0.07 for each dollar of current and long term assets held by the company. Unproductive assets utilization implies the company is being less competent with each dollar of current and long term assets it owns. Strictly speaking assets utilization of PTC Therapeutics shows how inefficient it operates for each dollar spent on its current and long term assets. The latest increase in of PTC Therapeutics short term price appreciation may encourage investors to take a closer look at the company as it closed today at a share price of 47.67 on 553290.000 in trading volume. The company directors and management have been quite successful with maneuvering the fund at opportune times to take advantage of all market conditions in November. The stock standard deviation of daily returns for 30 days (very short) investing horizon is currently 2.14. The current volatility is consistent with the ongoing market swings in November 2019 as well as with PTC Therapeutics unsystematic, company specific events. PTC Therapeutics reports 4.0 z score. PTC Therapeutics is selling at 48.38. That is 0.75 percent increase. Today lowest is 47.67. PTC Therapeutics Operating Margin is decreasing over the last 5 years. Also, PTC Therapeutics Net Income Common Stock USD is comparatively stable at the moment.
 2018 2019 (projected)
Revenues USD42.28 M49.59 M
Revenues264.73 M296.86 M
PTC Therapeutics, Inc., a biopharmaceutical company, focuses on the discovery, development, and commercialization of medicines for the treatment of rare disorders. PTC Therapeutics, Inc. was founded in 1998 and is headquartered in South Plainfield, New Jersey. PTC Therapeutics operates under Biotechnology classification in USA and is traded on BATS Exchange. It employs 511 people.
Revenues USDRevenues
On the whole, we believe that at this point PTC Therapeutics is not too volatile with low chance of bankruptcy within the next 2 years. Our overall buy-sell advice on the firm is Buy.

Building efficient market-beating portfolios requires time, education, and a lot of computing power!

The Portfolio Architect is an AI-driven system that provides multiple benefits to our users by leveraging cutting-edge machine learning algorithms, statistical analysis, and predictive modeling to automate the process of asset selection and portfolio construction, saving time and reducing human error for individual and institutional investors.

Try AI Portfolio Architect

Editorial Staff

Rifka Kats is a Member of Macroaxis Editorial Board. Rifka writes about retail product and service companies from the perspective of a regular consumer and sophisticated investor at the same time. She is passionate about corporate ethics and equality in the workforce. View Profile
This story should be regarded as informational only and should not be considered a solicitation to sell or buy any financial products. Macroaxis does not express any opinion as to the present or future value of any investments referred to in this post. This post may not be reproduced without the consent of Macroaxis LLC. Macroaxis LLC and Rifka Kats do not own shares of PTC Therapeutics. Please refer to our Terms of Use for any information regarding our disclosure principles.

Would you like to provide feedback on the content of this article?

You can get in touch with us directly or send us a quick note via email to editors@macroaxis.com
Macroaxis helps investors of all levels and skills to maximize the upside of all their holdings and minimize the risk associated with market volatility, economic swings, and company-specific events. View terms and conditions
 
Feedback Blog
Made with optimal in San Francisco
2024 Macroaxis LLC
COMMON DESTINATIONS
MAIN CATEGORIES
COMPANY